A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) (NCT02991469)

🧪 Interventions in This Study

• Sarilumab SAR153191 (REGN88) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

• Investigational Site Number : 0320004 — San Miguel de Tucumán, Tucumán Province
• Investigational Site Number : 0320005 — Buenos Aires,
• Investigational Site Number : 1240110 — Calgary, Alberta
• Investigational Site Number : 2460040 — Helsinki,
• Investigational Site Number : 2500041 — Bron,
• Investigational Site Number : 2500042 — Montpellier,
• Investigational Site Number : 2500040 — Paris,
• Investigational Site Number : 2760064 — Berlin,
• Investigational Site Number : 2760065 — Berlin,
• Investigational Site Number : 2760062 — Hamburg,
• Investigational Site Number : 2760060 — Sankt Augustin,
• Investigational Site Number : 2760063 — Sendenhorst,
• Investigational Site Number : 3000001 — Athens,
• Investigational Site Number : 3000002 — Thessaloniki,
• Investigational Site Number : 3720001 — Crumlin, Dublin
• Investigational Site Number : 3800051 — Genoa, Genova
• Investigational Site Number : 3800054 — Milan, Milano
• Investigational Site Number : 3800052 — Rome, Roma
• Investigational Site Number : 6200003 — Lisbon,
• Investigational Site Number : 6430001 — Moscow,
• Investigational Site Number : 6430062 — Moscow,
• Investigational Site Number : 6430063 — Moscow,
• Investigational Site Number : 6430065 — Ufa,
• Investigational Site Number : 7240055 — Barcelona, Barcelona [Barcelona]
• Investigational Site Number : 7240050 — Esplugues de Llobregat, Barcelona [Barcelona]

📞 Contact the Study Coordinator

Phone: (800) 633-1610

Email: Contact-Us@sanofi.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Juvenile Idiopathic Arthritis

• An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis — Little Rock, Arkansas
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. — Phoenix, Arizona
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Rosario,
• M3-JIA: Making Mindfulness Matter for Children With JIA — Hamilton, Ontario
• UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease — Calgary, Alberta

Explore by condition: All Juvenile Idiopathic Arthritis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.